Aleva Neurotherapeutics is a Swiss-based startup that specializes in the development and commercialization of Deep Brain Stimulation (DBS) technologies. Originating as a spin-off from the Swiss Federal Institute of Technology, the company's primary goal is to enhance the existing DBS treatment for patients suffering from neurological disorders. DBS is a medical procedure used to treat a variety of debilitating neurological symptoms—most commonly the debilitating symptoms of Parkinson’s disease, such as tremor, rigidity, stiffness, slowed movement, and walking problems.

Aleva has pioneered the directional mode of DBS, a more sophisticated technology that has set the industry standard for directional leads. This technology allows for more precise stimulation of specific areas of the brain, potentially reducing side effects and improving patient outcomes. The company holds 13 patent families and 90 granted patents in this area, demonstrating its expertise and commitment to innovation.

Aleva's business model revolves around partnering with leading neurological clinics in Europe, with plans to expand into worldwide markets in the near future. The company's revenue is generated through the sale of its directSTIM™ system, a DBS solution designed to eliminate surgical failures and non-responder patients. This system is fully manufactured and assembled in Switzerland, adhering to the highest quality standards.

In summary, Aleva Neurotherapeutics is a forward-thinking company dedicated to improving the lives of patients with neurological disorders through the development and commercialization of innovative DBS technologies.

Keywords: Aleva Neurotherapeutics, Deep Brain Stimulation (DBS), neurological disorders, directional mode, innovation, patent, directSTIM™ system, surgical failures, non-responder patients, Swiss Federal Institute of Technology.